(Q40358241)

19 September 2017

title

Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines (English)

1 reference

19 September 2017

11

A Holý

1 reference

19 September 2017

L Naesens

5

0 references

Christophe Pannecouque

C Pannecouque

7

0 references

Robert Snoeck

R Snoeck

8

0 references

Graciela Andrei

G Andrei

2

0 references

Erik De Clercq

Erik De Clercq

1

0 references

Jan Balzarini

3

J Balzarini

1 reference

19 September 2017

P Leyssen

4

1 reference

19 September 2017

J Neyts

6

1 reference

19 September 2017

C Ying

9

1 reference

19 September 2017

D Hocková

10

1 reference

19 September 2017

publication date

1 January 2005

1 reference

Nucleosides, Nucleotides & Nucleic Acids

19 September 2017

published in

1 reference

19 September 2017

volume

24

1 reference

19 September 2017

issue

5-7

1 reference

19 September 2017

page(s)

331-341

1 reference

Antiviral drugs in current clinical use.

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200059772

Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200059772

Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200059772

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200059772

Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200059772

Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200059772

Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200059772

6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200059772

Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200059772

5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200059772

Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200059772

6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200059772

A novel selective broad-spectrum anti-DNA virus agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200059772

Efficacy of cidofovir in a murine model of disseminated progressive vaccinia

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200059772

Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FNCN-200059772

21 January 2018

Identifiers

DOI

10.1081/NCN-200059772

1 reference

19 September 2017

1 reference